525.00
price up icon0.77%   4.00
after-market Handel nachbörslich: 525.00
loading

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

pulisher
Jun 18, 2025

Regeneron Pharmaceuticals (REGN) Announces Key Decisions from 20 - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Regeneron Shareholders Approve Key Proposals at 2025 Meeting - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Grove Bank & Trust Has $514,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Exchange Traded Concepts LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Factory Mutual Insurance Co. Buys 8,200 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

Regeneron Steps Back, TTAM Aims To Reclaim 23andMe - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron (REGN) Exits 23andMe Bidding War - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

PKO Investment Management Joint Stock Co Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Schaper Benz & Wise Investment Counsel Inc. WI - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Breakthroughs in Uveitis Treatment Market Drive Global Demand - openPR.com

Jun 17, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

23andme founder-led group outbids Regeneron for company - BioWorld MedTech

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Fifth Third Bancorp Sells 952 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki overcomes Regeneron in 23andMe assets battle - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Anne Wojcicki’s Nonprofit Tops Bid for 23andMe Assets - Contract Pharma

Jun 16, 2025
pulisher
Jun 16, 2025

Patient Data Revolution: New Blockchain Platform Challenges Regeneron's $600M 23andMe Data Grab - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

BDF Gestion Has $2.82 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Warther Private Wealth LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Mn Services Vermogensbeheer B.V. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid - The Globe and Mail

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

RMR Wealth Builders Acquires Shares of 2,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Osprey Private Wealth LLC Makes New $2.24 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Pallas Capital Advisors LLC Invests $426,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Sanofi: positive data in chronic rhinosinusitis - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Leerink Partnrs Issues Negative Forecast for REGN Earnings - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by NorthCrest Asset Manangement LLC - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Sanofi, Regeneron Report Encouraging Results from Head-to-head Respiratory Study - MarketScreener

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron (REGN) and Sanofi's Dupixent Shows Superior Results in Key Phase 4 Trial | REGN Stock News - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe … - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial for Nasal Polyps | REGN Stock News - Stock Titan

Jun 15, 2025
pulisher
Jun 15, 2025

Asio Capital LLC Has $2.53 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Wedmont Private Capital Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Assenagon Asset Management S.A. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Miracle Mile Advisors LLC - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Tounjian Advisory Partners LLC Invests $662,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Research Analysts Offer Predictions for REGN FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

23andMe co-founder Anne Wojcicki has bought back the company - NewsBytes

Jun 14, 2025
pulisher
Jun 13, 2025

23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Atwood & Palmer Inc. Has $26.62 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Anne Wojcicki to buy back 23andMe and its data for $305 million - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

Regeneron requests bundling ban after trial win - Global Competition Review

Jun 13, 2025
pulisher
Jun 13, 2025

Former 23andMe CEO wins bidding war against Regeneron - FirstWord

Jun 13, 2025
pulisher
Jun 13, 2025

23andMe's founder Anne Wojcicki wins bid for DNA testing firm - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

23andMe founder buys back genetic testing company in second auction - Financial Times

Jun 13, 2025
$326.09
price up icon 1.01%
$551.22
price down icon 1.59%
biotechnology ONC
$242.07
price up icon 0.36%
$106.47
price down icon 0.23%
$100.64
price up icon 1.16%
Kapitalisierung:     |  Volumen (24h):